BRAF and neoplasm: In our cohort of 13 patients (n = 5 BRAF V600E, n = 4 BRAF WT, n = 4 healthy controls) we characterize the mutant allele frequency in all tumor tissues as well as the plasma samples from patients with confirmed BRAFV600E gliomas.